Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Lebwohl

Showing results (181-190 of 418) with videos related to

Pageof 42
Sort By:
Dermatology and Therapy|July 18, 2021
A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment ParadigmBruce Strober, David Pariser, Ann Deren-Lewis, et al.
Journal of Drugs in Dermatology : JDD|April 7, 2023
Brodalumab: 4-Year US Pharmacovigilance ReportMark Lebwohl, John Koo, Craig Leonardi, et al.
Allergy|November 30, 2022
Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advancesAllen Kaplan, Mark Lebwohl, Ana M Giménez-Arnau, et al.
The British Journal of Dermatology|May 14, 2025
Efficacy and safety of tildrakizumab in patients with early- vs late-onset psoriasisApril W Armstrong, Andrew Blauvelt, Mark Lebwohl, et al.
International Journal of Dermatology|April 16, 2025
Management of Eczematous Reactions Secondary to Biologic Use in Psoriasis Patients: A Retrospective StudyShivkar Amara, Nilesh Kodali, Miyahra Lopez, et al.
Journal of the American Academy of Dermatology|August 21, 2007
Are patients with psoriasis undertreated? Results of National Psoriasis Foundation surveyElizabeth J Horn, Kathleen M Fox, Vaishali Patel, et al.
The Journal of Clinical and Aesthetic Dermatology|June 18, 2016
Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) is More Efficacious than Cal or BD Aerosol Foam Alone for Psoriasis Vulgaris: A Randomized, Double-blind, Multicenter, Three-arm, Phase 2 StudyMark Lebwohl, Stephen Tyring, Michael Bukhalo, et al.
Journal of the American Academy of Dermatology|September 1, 2025
Real-world treatment patterns in patients with generalized pustular psoriasis (GPP)Bruce Strober, Hannah Kwiatkowski, Layla Lavasani, et al.
Journal of the American Academy of Dermatology|April 18, 2015
Evaluating the economic burden of psoriasis in the United StatesJacqueline Vanderpuye-Orgle, Yang Zhao, Jackie Lu, et al.
Archives of Dermatology|June 18, 2003
An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasisMark Lebwohl, Enno Christophers, Richard Langley, et al.
Pageof 42

Showing results (181-190 of 418) with videos related to

Sort By:
Pageof 42
Dermatology and Therapy|July 18, 2021
A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment ParadigmBruce Strober, David Pariser, Ann Deren-Lewis, et al.
Journal of Drugs in Dermatology : JDD|April 7, 2023
Brodalumab: 4-Year US Pharmacovigilance ReportMark Lebwohl, John Koo, Craig Leonardi, et al.
Allergy|November 30, 2022
Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advancesAllen Kaplan, Mark Lebwohl, Ana M Giménez-Arnau, et al.
The British Journal of Dermatology|May 14, 2025
Efficacy and safety of tildrakizumab in patients with early- vs late-onset psoriasisApril W Armstrong, Andrew Blauvelt, Mark Lebwohl, et al.
International Journal of Dermatology|April 16, 2025
Management of Eczematous Reactions Secondary to Biologic Use in Psoriasis Patients: A Retrospective StudyShivkar Amara, Nilesh Kodali, Miyahra Lopez, et al.
Journal of the American Academy of Dermatology|August 21, 2007
Are patients with psoriasis undertreated? Results of National Psoriasis Foundation surveyElizabeth J Horn, Kathleen M Fox, Vaishali Patel, et al.
The Journal of Clinical and Aesthetic Dermatology|June 18, 2016
Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) is More Efficacious than Cal or BD Aerosol Foam Alone for Psoriasis Vulgaris: A Randomized, Double-blind, Multicenter, Three-arm, Phase 2 StudyMark Lebwohl, Stephen Tyring, Michael Bukhalo, et al.
Journal of the American Academy of Dermatology|September 1, 2025
Real-world treatment patterns in patients with generalized pustular psoriasis (GPP)Bruce Strober, Hannah Kwiatkowski, Layla Lavasani, et al.
Journal of the American Academy of Dermatology|April 18, 2015
Evaluating the economic burden of psoriasis in the United StatesJacqueline Vanderpuye-Orgle, Yang Zhao, Jackie Lu, et al.
Archives of Dermatology|June 18, 2003
An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasisMark Lebwohl, Enno Christophers, Richard Langley, et al.
Pageof 42